Finding ways to reduce side effects from cancer immunotherapy
Identification of pathways to mitigate Immune-Related Adverse Events with Cancer Immunotherapy
This study is looking at the skin-related side effects that some people experience when they receive cancer immunotherapy, and it aims to find out why these happen and how to manage them better, especially for those who may not respond well to standard treatments.
Quick facts
| Grant type | U01 cooperative agreement |
|---|---|
| Study type | NIH-funded research |
| Funding institution | National Jewish Health NIH-funded |
| Lab location | 1 site (Denver, United States) |
| Project ID | NIH-10806996 on NIH RePORTER |
What this research studies
This research investigates the immune-related adverse events (irAEs) that can occur in patients receiving cancer immunotherapy, specifically immune checkpoint inhibitors (CPIs). It aims to identify the underlying mechanisms that lead to these side effects, particularly those affecting the skin, and to develop strategies for better management. By analyzing the immune responses in patients with these adverse events, the study seeks to differentiate between those who respond to corticosteroid treatment and those who do not. This understanding could lead to more effective and targeted therapies for managing these side effects.
Who could benefit from this research
Good fit: Ideal candidates for this research are patients undergoing cancer treatment with immune checkpoint inhibitors who are experiencing immune-related adverse events.
Not a fit: Patients who are not receiving cancer immunotherapy or those who do not experience immune-related adverse events may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to improved management of side effects from cancer immunotherapy, enhancing patient quality of life and treatment adherence.
How similar studies have performed: Previous research has shown promise in understanding immune-related adverse events in cancer therapy, but this study aims to explore novel mechanisms and interventions.
Where this research is happening
Denver, United States
- National Jewish Health — Denver, United States (Active)
Researchers
- Principal investigator: Leung, Donald Ym — National Jewish Health
- Study coordinator: Leung, Donald Ym
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.